Program creation support device
    1.
    发明授权
    Program creation support device 有权
    程序创建支持设备

    公开(公告)号:US08843885B2

    公开(公告)日:2014-09-23

    申请号:US13503747

    申请日:2010-08-24

    IPC分类号: G06F9/44

    摘要: A program creation support device includes a program component creating, upon a user setting a content of a reuse parameter corresponding to each program element, a program in accordance with the set content, and a program component holding unit editing the program by reuse of that. The program component includes a program element creating, upon a plurality of parameters being enumerated and set in the reuse parameter, a program in which a plurality of elements corresponding to respective parameters are combined. The program creation support device can reduce efforts in the selection and combination of program components for creating a program conforming to predetermined specifications, to thereby enhance the efficiency of creating a program.

    摘要翻译: 程序创建支持设备包括:程序组件,用于根据所设置的内容,在用户设置与每个程序单元相对应的重用参数的内容上创建程序,以及程序组件保存单元,通过重用该程序组件来编辑该程序。 程序组件包括程序元件,在多个参数被枚举并在重用参数中设置时,创建一个程序,在该程序中组合了与各个参数对应的多个元素。 程序创建支持装置可以减少用于创建符合预定规范的程序的程序组件的选择和组合的努力,从而提高创建程序的效率。

    PROGRAM CREATION SUPPORT DEVICE
    2.
    发明申请
    PROGRAM CREATION SUPPORT DEVICE 有权
    程序创建支持设备

    公开(公告)号:US20120222001A1

    公开(公告)日:2012-08-30

    申请号:US13503747

    申请日:2010-08-24

    IPC分类号: G06F9/44

    摘要: A program creation support device includes a program component creating, upon a user setting a content of a reuse parameter corresponding to each program element, a program in accordance with the set content, and a program component holding unit editing the program by reuse of that. The program component includes a program element creating, upon a plurality of parameters being enumerated and set in the reuse parameter, a program in which a plurality of elements corresponding to respective parameters are combined. The program creation support device can reduce efforts in the selection and combination of program components for creating a program conforming to predetermined specifications, to thereby enhance the efficiency of creating a program.

    摘要翻译: 程序创建支持设备包括:程序组件,用于根据所设置的内容,在用户设置与每个程序单元相对应的重用参数的内容上创建程序,以及程序组件保存单元,通过重用该程序组件来编辑该程序。 程序组件包括程序元件,在多个参数被枚举并在重用参数中设置时,创建一个程序,在该程序中组合了与各个参数对应的多个元素。 程序创建支持装置可以减少用于创建符合预定规范的程序的程序组件的选择和组合的努力,从而提高创建程序的效率。

    SEQUENCE PROGRAM CREATING APPARATUS
    3.
    发明申请
    SEQUENCE PROGRAM CREATING APPARATUS 审中-公开
    顺序程序创建设备

    公开(公告)号:US20130104101A1

    公开(公告)日:2013-04-25

    申请号:US13519207

    申请日:2011-09-16

    IPC分类号: G06F9/44

    CPC分类号: G06F8/30 G05B19/056 G06F8/34

    摘要: A sequence program creating apparatus creates a sequence program to be executed by a programmable logic controller by causing a user to perform an operation of editing a sequential function chart (SFC) expressed by a plurality of elements and a connecting state thereof on an editing screen. The sequence program creating apparatus includes: a rule storage unit that stores therein a code of the SFC; and an editing control unit that, when a new-element inserting operation for newly inserting the element into the SFC is performed on the editing screen, adds data corresponding to the new element to data of the sequence program, based on a type of the already-arranged element specified as a new-element insertion target element by the new-element inserting operation, a position with respect to the new-element insertion target element, and a code of the SFC stored in the rule storage unit.

    摘要翻译: 序列程序创建装置通过使用户在编辑屏幕上执行编辑由多个元素表达的顺序功能图(SFC)及其连接状态的操作来创建由可编程逻辑控制器执行的顺序程序。 序列程序创建装置包括:规则存储单元,其中存储有SFC的代码; 以及编辑控制单元,当在编辑画面上执行用于将元素新插入到SFC的新元素插入操作时,根据已经存在的类型将与新元素相对应的数据添加到顺序程序的数据 通过新元素插入操作指定为新元素插入目标元素的相对于新元素插入目标元素的位置以及存储在规则存储单元中的SFC的代码。

    LADDER PROGRAM EDITION DEVICE
    4.
    发明申请
    LADDER PROGRAM EDITION DEVICE 审中-公开
    梯子程序编辑装置

    公开(公告)号:US20110295388A1

    公开(公告)日:2011-12-01

    申请号:US13147776

    申请日:2009-02-04

    IPC分类号: G05B19/05

    CPC分类号: G05B19/056 G05B2219/13196

    摘要: When constituting a ladder program edition device that edits a ladder diagram, there is provided an edit control unit that generates data of a logical expression corresponding to a logical structure of an input condition and an output condition in a ladder diagram based on an arrangement of circuit elements in a ladder diagram, sets circuit elements that specify the input condition as one circuit unit of one input and one output for each input condition based on the data of the above logical expression, and connects output ends of circuit units to be connected in parallel with each other in the ladder diagram. With this configuration, generation of a syntactically erroneous ladder diagram is prevented.

    摘要翻译: 当构成编辑梯形图的梯形图编辑装置时,提供了编辑控制单元,其基于电路的布置来生成与梯形图中的输入条件和输出条件的逻辑结构相对应的逻辑表达的数据 梯形图中的元件将基于上述逻辑表达式的数据将输入条件指定为一个输入的一个电路单元和每个输入条件的一个输出的电路元件,并且连接到并联的电路单元的输出端 在梯形图中彼此。 利用这种配置,可以防止生成语法错误的梯形图。

    Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same
    5.
    发明申请
    Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same 审中-公开
    包含ets转录因子或其编码基因的细胞增殖抑制剂

    公开(公告)号:US20050260582A1

    公开(公告)日:2005-11-24

    申请号:US10467945

    申请日:2002-02-13

    摘要: It is found out that an ETS transcription factor (more specifically, an ETS transcription factor MEF) has a potent effect of inhibiting cell proliferation and an effect of inhibiting MMP production. Based on this finding, novel cell proliferation inhibitors (more specifically, novel remedies for tumor and novel antirheumatics) with the use of the ETS transcription factor MEF or a gene encoding the same are provided. Namely, cell proliferation inhibitors comprising an ETS transcription factor or gene encoding the same or a substance controlling the effect of the ETS transcription factor or the gene encoding the same. Also, matrix metalloprotease (MMP) (more specifically, MMP-9) production inhibitors or IL-8 production inhibitors comprising the ETS transcription factor or gene encoding the same or a substance controlling the effect of the ETS transcription factor or the gene encoding the same are provided.

    摘要翻译: 发现ETS转录因子(更具体地说,ETS转录因子MEF)具有抑制细胞增殖的有效作用和抑制MMP生成的作用。 基于这一发现,提供了使用ETS转录因子MEF或编码其的基因的新型细胞增殖抑制剂(更具体地,用于肿瘤和新型抗风湿剂的新型治疗剂)。 即,包含ETS转录因子或编码该ETS转录因子的基因或控制ETS转录因子的作用的物质或编码该ETS转录因子的基因的细胞增殖抑制剂。 此外,包含ETS转录因子或编码其的基因金属蛋白酶(MMP)(更具体地,MMP-9)产生抑制剂或IL-8产生抑制剂或控制ETS转录因子的作用的物质或编码该ETS转录因子的基因 被提供。

    GM-CSF and/or defensin protein expression regulators in epithelial cells comprising ETS transcription factor or gene encoding the same
    6.
    发明申请
    GM-CSF and/or defensin protein expression regulators in epithelial cells comprising ETS transcription factor or gene encoding the same 审中-公开
    GM-CSF和/或防御素蛋白表达调节剂在包含ETS转录因子或编码该基因的基因的上皮细胞中

    公开(公告)号:US20060024728A1

    公开(公告)日:2006-02-02

    申请号:US11216245

    申请日:2005-08-30

    IPC分类号: C12Q1/68 C12P21/06 A61K48/00

    CPC分类号: A61K38/1709 A61K48/00

    摘要: To solve the problem of drug tolerence and side effects in antiinflammatory agents, immunosuprressive agents and antiviral agents having been put into practical use, it is intended to provide a novel therapy for inflammation and novel antiinflammatory agents with the use of an ETS transcription factor which regulates the gene expression of an inflammartory cytokine GM-CSF and a bactericidal peptide β--defensin. Namely, expression regulators for the inflammatory cytokine GM-CSF and/or β-defensin in epithelial cells and antiinflammatory agents which comprise an ETS transcription factor having a gene transcription regulatory activity or a gene encoding the same, or a substance regulating the function of ETS transcription factor or a gene encoding the same, more specifically, a transcription regulatory protein myeloid Elf-1 like factor (MEF) or a gene encoding the same, or a substance regulating the function of the MEF protein or a gene encoding the same. More specifically, inflammatory cytokine GM-CSF production inhibitors, and /or regulators for β-defensin expression due to overexpression, and antiinflammatory agents.

    摘要翻译: 为了解决已经投入实际应用的抗炎药,免疫抑制剂和抗病毒药物的药物易感和副作用的问题,旨在提供一种新的治疗炎症和新型抗炎药,其使用调节的ETS转录因子 炎症细胞因子GM-CSF和杀菌肽β-防御素的基因表达。 也就是说,包含具有基因转录调节活性的ETS转录因子的上皮细胞中的炎性细胞因子GM-CSF和/或β-防御素的表达调节剂和编码该基因转录调节活性的基因,或调节ETS功能的物质 转录因子或编码该基因的基因,更具体而言,是转录调节蛋白质的骨髓E1f-1样因子(MEF)或编码该基因的基因,或调节MEF蛋白的功能的物质或编码该基因的基因。 更具体地,炎性细胞因子GM-CSF产生抑制剂和/或由于过表达引起的β-防御素表达的调节剂和抗炎剂。

    Medicine for prevention of and treatment for amyloidosis
    7.
    发明申请
    Medicine for prevention of and treatment for amyloidosis 审中-公开
    用于预防和治疗淀粉样变性的药物

    公开(公告)号:US20060134228A1

    公开(公告)日:2006-06-22

    申请号:US10514335

    申请日:2003-05-13

    IPC分类号: A61K33/24 A61K31/555

    摘要: A pharmaceutical for the prophylaxis and/or treatment of amyloidosis such as familial amyloid polyneuropathy is provided. A pharmaceutical for the prophylaxis and/or treatment of amyloidosis that contains a compound containing the trivalent chromium ion, such as a fatty acid chromium salt, as an active ingredient, and that is capable of suppressing the decomposition of mutant transthyretin in amyloidosis.

    摘要翻译: 提供了用于预防和/或治疗淀粉样变性的药物,例如家族性淀粉样多发性神经病。 一种用于预防和/或治疗淀粉样变性的药物,其包含含有三价铬离子的化合物,例如脂肪酸铬盐作为活性成分,并且能够抑制淀粉样变性突变型转甲状腺素的分解。

    Method for treating immune complex diseases with n-acetylneuraminic acid
    8.
    发明授权
    Method for treating immune complex diseases with n-acetylneuraminic acid 失效
    用N-乙酰神经氨酸处理免疫复合物疾病的方法

    公开(公告)号:US5177062A

    公开(公告)日:1993-01-05

    申请号:US325649

    申请日:1989-03-20

    IPC分类号: A61K31/70

    CPC分类号: A61K31/7004

    摘要: A preparation for treating immune complex diseases which comprises injection containing the following compound: ##STR1## wherein when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, as an active ingredient and pharmacologically acceptable carrier. The preparation of the present invention may be used in any administration method such as hypodermic, intramuscular and intravenous.

    摘要翻译: 一种用于治疗免疫复合物疾病的制剂,其包含含有以下化合物的注射剂:其中当n为1时,Z表示氢,锂,钾,钠,铵或有机铵,当n为2时,Z表示钙, 钡或镁,作为活性成分和药理学上可接受的载体。 本发明的制剂可以以任何施用方法如皮下注射,肌内注射和静脉内使用。